炎症性肠病关节、皮肤和眼部肠外表现的药物治疗有效性:一项伞状综述
该伞状综述检索截至2024年5月30日的系统综述,评估炎症性肠病关节、皮肤和眼部肠外表现的药物治疗有效性与安全性。抗肿瘤坏死因子治疗对中轴型和外周关节炎显示较高应答率,乌司奴单抗对关节痛和银屑病关节炎有效但对中轴型脊柱关节炎无效,眼科肠外表现新发率在维得利珠单抗和乌司奴单抗为1%。证据异质性大且质量低,安全性数据有限。
要点
- 抗肿瘤坏死因子治疗中轴型关节炎应答率59.1%-61.8%,外周关节炎73.4%-81.2%。
- 维得利珠单抗治疗关节表现的改善程度最低。
- 维得利珠单抗和乌司奴单抗新发眼部肠外表现发生率为1%。
核心结论
- 炎症性肠病关节、皮肤和眼部肠外表现的药物治疗证据异质性大且质量低,需要进一步研究,包括多学科方法和新颖实用的终点评估方法。
研究设计与样本
- 伞状综述,检索三个数据库截至2024年5月30日发表的系统综述,由两名独立评价者进行筛选、数据提取和质量评价(AMSTAR-2)。
主要发现
- 分别有10篇、12篇和6篇系统综述提供关节、皮肤和眼部表现的药物治疗数据。
- 抗肿瘤坏死因子治疗对中轴型关节炎应答率59.1%-61.8%,对外周关节炎应答率73.4%-81.2%。
- 维得利珠单抗治疗关节表现的改善程度最低。
- 乌司奴单抗对关节痛和银屑病关节炎有效,但对中轴型脊柱关节炎无效。
- 抗肿瘤坏死因子、维得利珠单抗、乌司奴单抗和托法替布在不同皮肤表现中的应答异质性为21%-100%。
关键数值与推荐
- 抗肿瘤坏死因子治疗中轴型关节炎应答率59.1%-61.8%,外周关节炎73.4%-81.2%。
- 维得利珠单抗治疗关节表现改善最低;乌司奴单抗改善眼部症状55%-59%。
- 维得利珠单抗和乌司奴单抗新发眼部肠外表现发生率均为1%。
- 无系统综述评价IL-23 p40拮抗剂或其他口服小分子药物。
- 安全性数据有限,证据确定性为中至低。
局限性
- 证据异质性大且质量低。
- 安全性数据有限。
- 证据确定性为中至低。
- 需要进一步研究,包括多学科方法和新颖实用的终点评估方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extraintestinal manifestations (EIMs) occur commonly in patients with inflammatory bowel disease (IBD), affecting joints, skin, eyes and other organs, and contributing to morbidity and long-term disability. AIMS: To synthesise evidence from systematic reviews (SRs) on the effectiveness and safety of medical treatments for IBD EIMs in IBD of joints, skin and eyes. METHODS: For this umbrella review, we searched three databases for relevant SRs published until May 30, 2024. Two independent reviewers performed screening, data extraction and quality appraisal (AMSTAR-2). RESULTS: Ten, 12 and six SRs, respectively, provided data on medical therapies for articular, dermatological and ocular manifestations. Anti-TNF therapy showed high response rates for axial (59.1%-61.8%) and peripheral arthritis (73.4%-81.2%). The lowest improvement was in patients treated with vedolizumab for joint manifestations. Ustekinumab was effective for arthralgia and psoriatic arthritis, but not for axial spondylarthritis. High heterogeneity of response was reported for anti-TNF, vedolizumab, ustekinumab and tofacitinib (21%-100%) depending on the dermatological manifestation. No SRs evaluated IL-23 p40 antagonists or other oral small molecules. The incidence of new ocular EIMs was 1% for vedolizumab and ustekinumab. Anti-TNF agents were effective for most ocular EIM cases. Ustekinumab improved ocular symptoms in 55%-59%. Safety data were limited, with evidence certainty ranging from moderate to low. CONCLUSIONS: Evidence for medical therapies for joint, skin and eye EIMs in IBD is heterogeneous and of low quality. Further research is needed, including a multidisciplinary approach and novel and practical methods for endpoint evaluation.
引用
- Nardone OM, Noor NM, Prabhu A, et al. The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review. Aliment Pharmacol Ther. 2025. PMID: 40329548. doi:10.1111/apt.70181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。